Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

Oparil, Suzanne; Yarows, Steven A.; Patel, Samir N.; Fang, Hui; Zhang, Jack; Satlin, Andrew

doi:10.1016/s0140-6736(07)61124-6

Cited by 417 publications

(403 citation statements)

References 27 publications

Supporting

Mentioning

358

Contrasting

Unclassified

Order By: Relevance

“…Preliminary studies suggest that it may also prove to be effective in treatment of heart failure [29]. The observation that it has additive effects to ACE inhibitor or ARB dosing [30] is consistent with prior studies suggesting additive benefits when an ARB is added to an ACE inhibitor. The failure of additive benefit in a post-MI population [31] or in a population with atherosclerosis [32] has tempered the enthusiasm for combining two or three RAS inhibitors to achieve greater clinical benefit.…”

Section: R I a I A Ii At R At R Aldsupporting

confidence: 73%

Role of the Renin-Angiotensin System in Cardiovascular Disease

Cohn

2010

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Section: R I a I A Ii At R At R Aldsupporting

confidence: 73%

Role of the Renin-Angiotensin System in Cardiovascular Disease

Cohn

2010

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

“…Direct inhibition of renin with aliskerin has been shown to have beneficial effects on blood pressure, inflammation, fibrosis, and end-organ damage (155,243,256,333). A recent study, Aliskiren in the EValuation of PrOteinuria In Diabetes (AVOID) Trial, showed that the addition of a renin inhibitor to an ARB in diabetic and hypertensive patients decreases proteinuria further when compared with an ARB alone (251).…”

Section: B Role Of the Raas In Oxidative Stress And Hypertensionmentioning

confidence: 99%

Redox Control of Renal Function and Hypertension

Nistala

Whaley‐Connell

Sowers

2008

Antioxidants & Redox Signaling

139

123

View full text Add to dashboard Cite

“…[13][14][15] Aliskiren, an oral direct renin inhibitor, has been shown to be effective in lowering arterial BP as monotherapy or in combination with other anti-hypertensive drugs. [16][17][18] To date, aliskiren has not been prospec-tively evaluated in a controlled study in elderly patients with systolic hypertension. The purpose of this study (Aliskiren for GEriatric LowEring of SyStolic Hypertension: The AGELESS trial) was to compare the efficacy and safety of the direct renin inhibitor aliskiren compared with the ACE inhibitor ramipril for the treatment of essential systolic hypertension in elderly patients.…”

Section: Introductionmentioning

confidence: 99%

Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial

et al. 2009

View full text Add to dashboard Cite

Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind, parallel-group, active-controlled, optional-titration study was performed in 901 patients (aliskiren, n ¼ 457; ramipril, n ¼ 444) X65 years of age with systolic blood pressure (SBP) X140 mm Hg. Aliskiren 150-300 mg per day or ramipril 5-10 mg per day for was administered for 12 weeks with optional add-on therapy of hydrochlorothiazide (12.5-25 mg per day) at week 12 and amlodipine (5-10 mg per day) at week 22. The primary end point was non-inferiority of aliskiren vs ramipril monotherapy for change from baseline in mean sitting SBP (msSBP) at week 12. Decreases from baseline msSBP and mean sitting diastolic BP with aliskiren monotherapy (À14.0 and À5.1 mm Hg, respectively) were non-inferior (Po0.001 for both values) and superior to ramipril monotherapy (À11.6, À3.6 mm Hg; P ¼ 0.02, Po0.01, respectively). More patients achieved BP control with aliskiren (42%) than ramipril (33%; Po0.01). At week 36, fewer patients receiving aliskiren-based therapy required add-on treatment with hydrochlorothiazide or amlodipine (P ¼ 0.01 and 0.048, respectively). Tolerability was similar, but more patients receiving ramipril reported cough (Po0.001). In elderly patients with systolic hypertension, aliskiren proved to be more effective and better overall anti-hypertensive therapy compared to ramipril.

show abstract

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

Cited by 417 publications

References 27 publications

Role of the Renin-Angiotensin System in Cardiovascular Disease

Role of the Renin-Angiotensin System in Cardiovascular Disease

Redox Control of Renal Function and Hypertension

Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial

Contact Info

Product

Resources

About